| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7229613 | DAIICHI SANKYO INC | Method for lowering serum glucose |
Apr, 2022
(1 year, 5 months ago) | |
Welchol is owned by Daiichi Sankyo Inc.
Welchol contains Colesevelam Hydrochloride.
Welchol has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Welchol are:
- US7229613
Welchol was authorised for market use on 03 April, 2019.
Welchol is available in bar, chewable;oral dosage forms.
Welchol can be used as a method for reducing serum glucose levels in adults with type 2 diabetes mellitus.
The generics of Welchol are possible to be released after 17 April, 2022.
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2019
Treatment: A method for reducing serum glucose levels in adults with type 2 diabetes mellitus
Dosage: BAR, CHEWABLE;ORAL
WELCHOL family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7229613 | DAIICHI SANKYO | Method for lowering serum glucose |
Apr, 2022
(1 year, 5 months ago) | |
|
US7229613 (Pediatric) | DAIICHI SANKYO | Method for lowering serum glucose |
Oct, 2022
(11 months ago) | |
Welchol is owned by Daiichi Sankyo.
Welchol contains Colesevelam Hydrochloride.
Welchol has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Welchol are:
- US7229613
- US7229613*PED
Welchol was authorised for market use on 02 October, 2009.
Welchol is available in for suspension;oral dosage forms.
Welchol can be used as treatment of type 2 diabetes mellitus.
The generics of Welchol are possible to be released after 20 October, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Oct 20, 2024 |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 02 October, 2009
Treatment: Treatment of type 2 diabetes mellitus
Dosage: FOR SUSPENSION;ORAL
WELCHOL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic